Scientific Advisors

Chemistry and formulation

Read more
This is some text inside of a div block.
Portrait photo

Tobias Rein

Scientific advisor / Chemistry and formulation
Read more
Read more
This is some text inside of a div block.
Portrait photo

Ingemar Starke

Scientific advisor / Chemistry and formulation
Read more

Clinical

Read more
This is some text inside of a div block.
Portrait photo

Andrew Rice

Scientific advisor / clinical
Read more
Read more
This is some text inside of a div block.
Portrait photo

Roger Knaggs

Scientific advisor / clinical
Read more

Pain

Regulatory

Read more
This is some text inside of a div block.
Portrait photo

Ann Christine Korsgaard

Scientific advisor / regulatory
Read more

Toxicology

Read more
This is some text inside of a div block.
Portrait photo

Urban Fagerholm

Scientific advisor / toxicology
Read more

Latest news

View all
October 3, 2023

Phase I study completed for PN6047

In August 2022, PharmNovo initiated the First-In-Human, (FIH), clinical study for the company’s drug candidate PN6047, aimed at evaluating its safety and tolerability. By August 2023, the study was completed, involving 104 subjects across 13 cohorts, which included both Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) cohorts. Each cohort consisted of 8 subjects, with 6 receiving active treatment and 2 receiving placebo.

Read more
October 3, 2023

PharmNovo presented at the BioStock Investor Meeting

PharmNovo participated at the BioStock Investor Meeting in Stockholm on September 20. Our CEO presented the development and phase I clinical study of our drug candidate PN6047, which is in its final phase.

Read more
September 28, 2023

No abuse potential shown in preclinical studies

We are delighted to share promising preclinical results for our innovative drug candidate PN6047, further confirming its safety profile. PN6047 is designed to provide relief from neuropathic pain, and these findings reinforce our commitment to safe and effective pain management as we prepare for Phase II trials in 2024.

Read more
September 10, 2023

Latest progress from PharmNovo at EFIC

PharmNovo will participate in the 13th Congress of the European Pain Federation, EFIC, in Budapest from 20-22 September. The EFIC Congress is the largest international congress on pain.

Read more